Prolactin family receptors form homodimers in the presence of their respective ligands, associate exclusively with Jak2 and signal via Stat5.

* Key recommended reading is highlighted with an asterisk

* Cabrera-Reyes EA, Limón-Morales O, Rivero-Segura NA, Camacho-Arroyo I, Cerbón M. (2017) Prolactin function and putative expression in the brain. Endocrine, 57 (2): 199-213. [PMID:28634745]

* Goffin V. (2017) Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. Pharmacol Ther, 179: 111-126. [PMID:28549597]

1. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM et al.. (2006) Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol, 34 (10): 1303-11. [PMID:16982323]

2. Frantz WL, MacIndoe JH, Turkington RW. (1974) Prolactin receptors: characteristics of the particulate fraction binding activity. J Endocrinol, 60 (3): 485-97. [PMID:4362846]

3. Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa V, Rosenfeld RG, Fima E, Hart G. (2016) In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone. Mol Pharm, 13 (2): 631-9. [PMID:26713839]

4. Marsilje TH, Alper PB, Lu W, Mutnick D, Michellys PY, He Y, Karanewsky DS, Chow D, Gerken A, Lao J et al.. (2008) Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold. Bioorg Med Chem Lett, 18 (19): 5259-62. [PMID:18783949]

5. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML et al.. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med, 342 (16): 1171-7. [PMID:10770982]